Experience

Davis Polk advised the initial purchaser in a Rule 144A/Regulation S offering by Cleveland-Cliffs Inc. of $750 million aggregate principal amount of its 5.875% senior guaranteed notes due…

Davis Polk advised the initial purchasers on a Rule 144A and Regulation S reopening of $50 million aggregate principal amount of 7.500% senior secured notes due 2028 of AI…

Davis Polk advised The Royal Bank of Scotland Group plc, a public limited company incorporated under the laws of Scotland, in connection with its SEC-registered shelf takedown of $1.25…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by Textron Inc. of $300 million aggregate principal amount of its 3.900%…

Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…

Davis Polk advised the initial purchasers in connection with the offering by Sociedad Química y Minera de Chile S.A. of $450 million aggregate principal amount of its 4.250% notes due 2029…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares representing 9,019,608 ordinary shares of the company. The ADSs…

Davis Polk advised the representative of the initial purchasers in connection with Rule 144A/Regulation S offerings by JBS USA Lux S.A., JBS USA Food Company and JBS USA Finance, Inc…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…

Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…